{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:53:44Z","timestamp":1790967224946,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.disamonth.2026.102113","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:33:34Z","timestamp":1776288814000},"page":"102113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review"],"prefix":"10.1016","volume":"72","author":[{"given":"Praveen","family":"Gunasekaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pugazhendi","family":"Inban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashita","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna Sakthi","family":"Aravazhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halla","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarshi","family":"Prajjwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobby","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.disamonth.2026.102113_bib0001","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2147\/DMSO.S540103","article-title":"Obesity and Its Comorbidities: current treatment options, emerging biological mechanisms, future perspectives and challenges","volume":"18","author":"Wang","year":"2025","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.disamonth.2026.102113_bib0002","doi-asserted-by":"crossref","first-page":"E984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.disamonth.2026.102113_bib0003","doi-asserted-by":"crossref","first-page":"9715","DOI":"10.3390\/ijms26199715","article-title":"Obesity-driven metabolic disorders: the interplay of inflammation and mitochondrial dysfunction","volume":"26","author":"Choi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2026.102113_bib0004","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.apsb.2023.01.012","article-title":"Pathophysiology of obesity and its associated diseases","volume":"13","author":"Jin","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.disamonth.2026.102113_sbref0005","series-title":"Over 1 Billion People Projected To Live With Obesity By 2030, Warns New World Obesity Atlas - Health Policy Watch","author":"Santos","year":"2022"},{"key":"10.1016\/j.disamonth.2026.102113_bib0006","unstructured":"Organization WH. Global nutrition targets 2030: childhood overweight brief 2025."},{"key":"10.1016\/j.disamonth.2026.102113_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177850","article-title":"Recent progress in the pharmacotherapy for obesity","volume":"1002","author":"Lu","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.disamonth.2026.102113_bib0009","article-title":"Pharmacological treatments for adults with overweight and obesity without diabetes","volume":"2024","author":"Shang","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.disamonth.2026.102113_bib0010","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJMcibr2409089","article-title":"Discovery of GLP-1\u2013based drugs for the treatment of obesity","volume":"392","author":"Drucker","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0011","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2020","journal-title":"Mol Metab"},{"key":"10.1016\/j.disamonth.2026.102113_bib0012","first-page":"1","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.disamonth.2026.102113_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/ijms27010027","article-title":"The roles of incretin hormones GIP and GLP-1 in metabolic and cardiovascular health: a comprehensive review","volume":"27","author":"Yamanouchi","year":"2026","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2026.102113_bib0014","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2024.1530811","article-title":"GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks","volume":"5","author":"Ilias","year":"2025","journal-title":"Front Clin Diabetes Healthc"},{"key":"10.1016\/j.disamonth.2026.102113_bib0016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13300-020-00816-y","article-title":"Drug therapy in obesity: a review of current and emerging treatments","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.disamonth.2026.102113_bib0017","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/life13041012","article-title":"A comprehensive review on weight loss associated with anti-diabetic medications","volume":"13","author":"Haddad","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.disamonth.2026.102113_bib0018","first-page":"1","article-title":"Pharmacotherapy for obesity: moving towards efficacy improvement","volume":"16","author":"Coutinho","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.disamonth.2026.102113_bib0019","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.disamonth.2026.102113_bib0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0022","article-title":"GLP\u22121 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102113_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.disamonth.2026.102113_bib0024","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000833","article-title":"Oral GLP-1 receptor agonists for weight loss","author":"Krinsky","year":"2024","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.disamonth.2026.102113_bib0025","article-title":"Wegovy now comes in pill form \u2014 here\u2019s what to know","author":"Brincat","year":"2026","journal-title":"Live Science"},{"key":"10.1016\/j.disamonth.2026.102113_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.disamonth.2026.102113_bib0027","doi-asserted-by":"crossref","first-page":"285","DOI":"10.14740\/jocmr6231","article-title":"Comparative efficacy of tirzepatide vs. semaglutide in reducing body weight in humans: a systematic review and meta-analysis of clinical trials and real-world data","volume":"17","author":"Bin","year":"2025","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.disamonth.2026.102113_bib0028","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev-pharmtox-031124-101146","article-title":"Evolving approaches for pharmacological therapy of obesity","volume":"65","author":"Chao","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0029","first-page":"291","article-title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Abdrabou Abouelmagd","year":"2025","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.disamonth.2026.102113_bib0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0031","article-title":"A probable case of tirzepatide-induced acute pancreatitis","volume":"17","author":"Sumaruth","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102113_bib0032","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5144\/0256-4947.2025.129","article-title":"Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis","volume":"45","author":"Safwan","year":"2025","journal-title":"Ann Saudi Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0033","unstructured":"MHRA Warns of Rare Severe Pancreatitis With GLP-1 Drugs n.d. https:\/\/www.medscape.com\/viewarticle\/mhra-warns-rare-severe-pancreatitis-glp-1-drugs-2026a100032y?form=fpf (accessed February 5, 2026)."},{"key":"10.1016\/j.disamonth.2026.102113_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.disamonth.2026.102113_bib0035","unstructured":"GLP-1RA and thyroid cancer: New study suggests detection bias, not causation - Mayo Clinic n.d. https:\/\/www.mayoclinic.org\/medical-professionals\/endocrinology\/news\/glp-1ra-and-thyroid-cancer-new-study-suggests-detection-bias-not-causation\/mac-20587812 (accessed February 5, 2026)."},{"key":"10.1016\/j.disamonth.2026.102113_bib0036","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients","volume":"86","author":"Galli","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0037","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.disamonth.2026.102113_bib0038","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-24-0046","article-title":"GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms","volume":"263","author":"Mullur","year":"2024","journal-title":"J Endocrinol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0039","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41591-023-02669-x","article-title":"Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity","volume":"30","author":"Waldrop","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.124.069680","article-title":"Digital footprints of obesity treatment: GLP-1 receptor agonists and the health equity divide","volume":"150","author":"Azizi","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.disamonth.2026.102113_bib0041","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S2213-8587(21)00240-0","article-title":"Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis","volume":"9","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0042","doi-asserted-by":"crossref","DOI":"10.1155\/jobe\/9919810","article-title":"Harnessing GLP-1 receptor agonists for obesity treatment: prospects and obstacles on the horizon","volume":"2025","author":"Abdelrahman","year":"2025","journal-title":"J Obes"},{"key":"10.1016\/j.disamonth.2026.102113_bib0043","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.disamonth.2026.102113_bib0044","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/cen.15262","article-title":"The efficacy of semaglutide on hypothalamic obesity caused by craniopharyngioma surgery","volume":"103","author":"Wang","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.disamonth.2026.102113_bib0045","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/dom.70244","article-title":"Digital engagement enhances dual GIP\/GLP-1 receptor agonist and GLP-1 receptor agonist efficacy: a retrospective cohort analysis of a digital weight loss service on outcomes and safety","volume":"28","author":"Johnson","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102113_bib0046","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/dom.70216","article-title":"Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: a multicentre real-world study","volume":"28","author":"Lambert","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102113_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10050985","article-title":"Clinical effectiveness and safety of once-weekly GLP-1 receptor agonist dulaglutide as add-on to metformin or metformin plus insulin secretagogues in obesity and type 2 diabetes","volume":"10","author":"Mirabelli","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1593334","article-title":"Oral semaglutide for the treatment of obesity: a retrospective real-world study","volume":"16","author":"Krajnc","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102113_bib0049","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity reply","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0050","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","article-title":"Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial","volume":"158","author":"Mok","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.disamonth.2026.102113_bib0051","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0052","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1089\/dia.2023.0490","article-title":"Efficacy of semaglutide in overweight and obese patients with type 1 diabetes","volume":"26","author":"Garg","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.disamonth.2026.102113_bib0053","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/ibd\/izae090","article-title":"Effectiveness and safety of semaglutide for weight loss in patients with inflammatory bowel disease and obesity","volume":"31","author":"Desai","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.disamonth.2026.102113_bib0054","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1580159","article-title":"Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity","volume":"16","author":"Ouyang","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102113_bib0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/dia.2024.0050","article-title":"Efficacy and safety of tirzepatide in overweight and obese adult patients with type 1 diabetes","volume":"26","author":"Garg","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.disamonth.2026.102113_bib0056","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2018.00784","article-title":"Feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity","volume":"9","author":"Cuomo","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102113_bib0058","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4126995","article-title":"Efficacy and safety of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus: a randomised controlled clinical trial in Tianjin, China","author":"Zhaohu","year":"2022","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.disamonth.2026.102113_bib0059","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.disamonth.2026.102113_bib0060","doi-asserted-by":"crossref","first-page":"e2165","DOI":"10.1002\/hsr2.2165","article-title":"The cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.disamonth.2026.102113_bib0061","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes : a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.111999","article-title":"Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight\/obesity: a systematic review and network meta-analysis","volume":"222","author":"Wen","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.disamonth.2026.102113_bib0063","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S2213-8587(24)00098-6","article-title":"Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review","volume":"12","author":"Alsaqaaby","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100682","article-title":"GLP-1 RA for cardiometabolic risk reduction in obesity \u2013 how do we best describe benefit and value?","volume":"18","author":"Kumar","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0066","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-025-02608-9","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges","volume":"24","author":"Westermeier","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0067","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5005\/jp-journals-10018-1437","article-title":"Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in persons with obesity and type 2 diabetes mellitus: a cross-sectional study","volume":"14","author":"Latif","year":"2024","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0068","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4727390","article-title":"The mechanism of metabolic influences on the endogenous GLP-1 by oral antidiabetic medications in type 2 diabetes mellitus","volume":"2020","author":"Nguyen","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.disamonth.2026.102113_bib0069","article-title":"GLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection","volume":"16","author":"Wang","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102113_bib0070","article-title":"Unlocking the multifaceted roles of GLP-1: physiological functions and therapeutic potential","volume":"14","author":"AL-Noshokaty","year":"2025","journal-title":"Toxicol Rep"},{"key":"10.1016\/j.disamonth.2026.102113_bib0071","first-page":"1","article-title":"Efficacy and safety of GLP-1 agonists in the treatment of T2DM: a systematic review and network meta-analysis","volume":"15","author":"Ren","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.disamonth.2026.102113_bib0072","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1186\/s12876-025-04358-0","article-title":"Efficacy of GLP-1 receptor agonists and dual GLP-1\/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials","volume":"25","author":"Tamilwanan","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0073","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11739-023-03237-4","article-title":"Pharmacotherapy for chronic obesity management: a look into the future","volume":"18","author":"Abdel-Malek","year":"2023","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0074","first-page":"1915","article-title":"GLP-1 receptor agonists as a breakthrough therapy for obesity and metabolic syndrome: a systematic review of efficacy and long-term outcomes","volume":"31","author":"Alyassi","year":"2024","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0075","article-title":"Tirzepatide versus semaglutide for weight loss in overweight and obese adults: a systematic review and meta-analysis of direct comparative studies","volume":"17","author":"Munawar","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102113_bib0076","article-title":"Semaglutide versus other glucagon-like peptide-1 agonists for weight loss in type 2 diabetes patients: a systematic review and meta-analysis","volume":"16","author":"Wen","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102113_bib0077","doi-asserted-by":"crossref","DOI":"10.12775\/QS.2024.30.56469","article-title":"Semaglutide, liraglutide and tirzepatide: comparison of effectiveness in the treatment of obesity \u2013 a literature review","volume":"30","author":"Baran","year":"2024","journal-title":"Qual Sport"},{"key":"10.1016\/j.disamonth.2026.102113_bib0078","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11096-024-01779-x","article-title":"Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Liu","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.disamonth.2026.102113_bib0079","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-024-03896-z","article-title":"Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial","volume":"86","author":"Qin","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.disamonth.2026.102113_bib0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/oby.23612","article-title":"Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program","volume":"31","author":"le Roux","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.disamonth.2026.102113_bib0081","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70082","article-title":"Efficacy of GLP-1 receptor agonist-based therapies on cardiovascular events and cardiometabolic parameters in obese individuals without diabetes: a meta-analysis of randomized controlled trials","volume":"17","author":"Yin","year":"2025","journal-title":"J Diabetes"},{"key":"10.1016\/j.disamonth.2026.102113_bib0082","article-title":"Cardiovascular benefits of glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes mellitus with atherosclerotic cardiovascular disease: a systematic review of randomized controlled trials","volume":"17","author":"Ahmad","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102113_bib0083","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis","volume":"30","author":"Ansari","year":"2024","journal-title":"Endocr Pract"},{"key":"10.1016\/j.disamonth.2026.102113_bib0084","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1438318","article-title":"Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis","volume":"16","author":"Karimi","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0085","first-page":"45","article-title":"Impact of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a systematic review","volume":"24","author":"Almutairi","year":"2025","journal-title":"Bangladesh J Med Sci"},{"key":"10.1016\/j.disamonth.2026.102113_bib0086","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/jcm13164674","article-title":"Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs","volume":"13","author":"Le","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0087","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.disamonth.2026.102113_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1613610","article-title":"Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis","volume":"16","author":"Xie","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0089","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.disamonth.2026.102113_bib0090","doi-asserted-by":"crossref","DOI":"10.1155\/jobe\/3897161","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for obesity management in adults with and without type 2 diabetes: a systematic review","volume":"2025","author":"Velji-Ibrahim","year":"2025","journal-title":"J Obes"},{"key":"10.1016\/j.disamonth.2026.102113_bib0091","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26502\/aimr.0189","article-title":"Double-edged sword with risks and benefits","volume":"8","author":"Pillarisetti","year":"2025","journal-title":"Arch Intern Med Res"},{"key":"10.1016\/j.disamonth.2026.102113_bib0092","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102113_bib0093","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/ph18050668","article-title":"The efficacy and safety of tirzepatide in patients with diabetes and\/or obesity: systematic review and meta-analysis of randomized clinical trials","volume":"18","author":"Liu","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.disamonth.2026.102113_bib0094","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1214334","article-title":"Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102113_bib0095","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0001130648.55090.4f","article-title":"S797 gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists used for weight loss: a real-world cohort study","volume":"120","author":"Alsakarneh","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0096","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.disamonth.2026.102113_bib0097","doi-asserted-by":"crossref","DOI":"10.1177\/20420188251406456","article-title":"GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications","volume":"16","author":"Ram\u00edrez-Mej\u00eda","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.disamonth.2026.102113_bib0098","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11938-024-00452-6","article-title":"Glucagon-like peptide 1 receptor agonists for obesity: efficacy, side effects, and risks","volume":"22","author":"Thota-Kammili","year":"2024","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.disamonth.2026.102113_bib0099","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.2147\/DMSO.S537229","article-title":"Comparative safety of GLP-1\/GIP co-agonists versus GLP-1 receptor agonists for weight loss in patients with obesity or overweight: a systematic review","volume":"18","author":"Xie","year":"2025","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.disamonth.2026.102113_bib0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial","volume":"25","author":"Neves","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102113_bib0101","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70080","article-title":"Analysis of reporting trends of serious adverse events associated with anti-obesity drugs","volume":"13","author":"Rai\u010devi\u0107","year":"2025","journal-title":"Pharmacol Res Perspect"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502926000519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502926000519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:25:07Z","timestamp":1779801907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502926000519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0011502926000519"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2026.102113","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2026.102113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102113"}}